JP2000507554A - 治療用アルキル化剤の毒性から保護する遺伝子治療のための変異型アルキルトランスフェラーゼの使用 - Google Patents
治療用アルキル化剤の毒性から保護する遺伝子治療のための変異型アルキルトランスフェラーゼの使用Info
- Publication number
- JP2000507554A JP2000507554A JP9534606A JP53460697A JP2000507554A JP 2000507554 A JP2000507554 A JP 2000507554A JP 9534606 A JP9534606 A JP 9534606A JP 53460697 A JP53460697 A JP 53460697A JP 2000507554 A JP2000507554 A JP 2000507554A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- agt
- mutant
- hematopoietic
- transduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.宿主たる哺乳動物の腫瘍疾患を治療する方法であって、該方法は、化学療 法処置に化合物を追加するステップを含み、前記化合物は、少なくとも1つの非 悪性細胞タイプに供給する間、腫瘍細胞に発現された蛋白質を不活性化し、核酸 のシーケンスは、腫瘍細胞において抑制された機能に関する活性を保持すると共 に、前記化合物に対する耐性を授与する突然変異蛋白質を発現する。 2.宿主たる哺乳動物はヒトである、請求項1に記載の方法。 3.化学療法処置は、抗腫瘍アルキル化剤又は抗腫瘍メチル化剤を含む、請求 項2に記載の方法。 4.非悪性細胞タイプは、造血細胞である、請求項3に記載の方法。 5.腫瘍細胞において発現された蛋白質は、O6−アルキルグアニン−DNAアル キルトランスフェラーゼである、請求項5に記載の方法。 6.化合物は、dBG、すなわちBGの2’−デオキシリボヌクレオシドアナログ である、請求項5に記載の方法。 7.化合物は、ピリミジン誘導体である、請求項5に記載の方法。 8.化合物は、O6−ベンジル化グアニン誘導体である、請求項5に記載の方 法。 9.O6−ベンジル化グアニン誘導体は、O6−ベンジルグアニンである、請求 項8に記載の方法。 10.造血細胞は、MFG-hAGT/P140Aにより形質導入される、請求項9に記載の方 法。 11.造血細胞は、MFG-hAGT/G156A(ΔMGMT)により形質導入される、請求項9に 記載の方法。 12.抗腫瘍アルキル化剤を追加することにより、宿主たる哺乳動物の腫瘍疾患 を治療する方法であって、以下のステップを含む: (a)前記宿主から造血幹細胞及び造血プロジェニター細胞を収集するステッ プ; (b)突然変異蛋白質を発現する核酸シーケンスを含む組換えベクターにより 、前記造血幹細胞及び造血プロジェニター細胞の集団を形質導入するステップで あって、該ステップにより、形質導入された造血細胞に突然変異蛋白質が生じる ; (c)O6−ベンジル化グアニン化合物を化学療法処置に追加するステップであ って、前記化合物は、腫瘍細胞に発現されたO6−アルキルグアニン−DNAア ルキルトランスフェラーゼ蛋白質を不活性化するものである; (d)前記突然変異蛋白質の発現により、腫瘍細胞にお ける抑制される機能に関して野生種の活性が保持されると共に、前記O6− ベンジル化グアニン化合物に対する耐性が授与されるように、前記形質導入され た造血細胞を前記哺乳動物の宿主に導入するステップ。 13.宿主たる哺乳動物はヒトである、請求項12に記載の方法。 14.造血細胞は、周囲の血液からの強化されたCD34+細胞である、請求項13 に記載の方法。 15.O6−ベンジル化グアニン誘導体は、O6−ベンジルグアニンである、請求 項14に記載の方法。 16.組換えベクターは、MFG-hAGT/P140Aである、請求項14に記載の方法。 17.組換えベクターは、MFG-hAGT/P140Aである、請求項15に記載の方法。 18.組換えベクターは、MFG-hAGT/G156A(ΔMGMT)である、請求項14に記載の 方法。 19.組換えベクターは、MFG-hAGT/G156A(ΔMGMT)である、請求項15に記載の 方法。 20.形質導入された細胞において、第2形質導入遺伝子を優勢に選択する方法 であって、該方法は、 O6−ベンジル化グアニン誘導体に対し耐性を有するAGT突然変異体を発現 する第1遺伝子を形質導入するステップと、 O6−ベンジル化グアニン誘導体と、アルキル化剤又はメチル化剤との存在下 で、標的細胞における形質導入された集団を共同で培養するステップを含む。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/620,969 | 1996-03-25 | ||
US08/620,969 US5965126A (en) | 1996-03-25 | 1996-03-25 | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
PCT/US1997/004917 WO1997035477A1 (en) | 1996-03-25 | 1997-03-25 | Use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000507554A true JP2000507554A (ja) | 2000-06-20 |
JP2000507554A5 JP2000507554A5 (ja) | 2004-12-02 |
Family
ID=24488165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9534606A Pending JP2000507554A (ja) | 1996-03-25 | 1997-03-25 | 治療用アルキル化剤の毒性から保護する遺伝子治療のための変異型アルキルトランスフェラーゼの使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5965126A (ja) |
EP (1) | EP0910246B1 (ja) |
JP (1) | JP2000507554A (ja) |
AT (1) | ATE477815T1 (ja) |
AU (1) | AU2548197A (ja) |
DE (1) | DE69739964D1 (ja) |
ES (1) | ES2355677T3 (ja) |
WO (1) | WO1997035477A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525606A (en) | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
US20040022838A1 (en) * | 2001-06-20 | 2004-02-05 | Holick Michael F. | Regulation of cell proliferation and differentiation using topically applied peptides |
US9682106B2 (en) | 2011-04-20 | 2017-06-20 | The Regents Of The University Of California | Method for combined conditioning and chemoselection in a single cycle |
EP3799876A1 (en) | 2011-04-20 | 2021-04-07 | The Regents of the University of California | Method for combined conditioning and chemoselection in a single cycle |
CN107709353A (zh) * | 2014-12-02 | 2018-02-16 | 普拉斯派克特查特凯尔Rwmc有限责任公司 | 治疗癌症的方法和组合物 |
BR112020001132A2 (pt) | 2017-07-18 | 2020-07-21 | Calimmune, Inc. | interruptor modulável para seleção de células doadoras modificadas |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352669A (en) * | 1990-03-13 | 1994-10-04 | The Of The United States Of America As Represented By The Department Of Health And Human Services | O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity |
US5091430A (en) * | 1990-03-13 | 1992-02-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | O6 -substituted guanine compounds and methods for depleting O6 -alkylguanine-DNA alkyltransferase levels |
ATE163046T1 (de) * | 1990-10-31 | 1998-02-15 | Somatix Therapy Corp | Genetische veränderung von endothelzellen |
US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
-
1996
- 1996-03-25 US US08/620,969 patent/US5965126A/en not_active Expired - Lifetime
-
1997
- 1997-03-25 AT AT97917019T patent/ATE477815T1/de not_active IP Right Cessation
- 1997-03-25 WO PCT/US1997/004917 patent/WO1997035477A1/en active Application Filing
- 1997-03-25 ES ES97917019T patent/ES2355677T3/es not_active Expired - Lifetime
- 1997-03-25 AU AU25481/97A patent/AU2548197A/en not_active Abandoned
- 1997-03-25 JP JP9534606A patent/JP2000507554A/ja active Pending
- 1997-03-25 DE DE69739964T patent/DE69739964D1/de not_active Expired - Lifetime
- 1997-03-25 EP EP97917019A patent/EP0910246B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0910246A4 (en) | 2003-07-02 |
EP0910246B1 (en) | 2010-08-18 |
ATE477815T1 (de) | 2010-09-15 |
AU2548197A (en) | 1997-10-17 |
DE69739964D1 (de) | 2010-09-30 |
EP0910246A1 (en) | 1999-04-28 |
WO1997035477A1 (en) | 1997-10-02 |
ES2355677T3 (es) | 2011-03-30 |
US5965126A (en) | 1999-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3867033B2 (ja) | 疾患の治療的処置および予防のためにbcl−2を用いる方法 | |
Nita et al. | Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo | |
Allay et al. | Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells | |
KR100395420B1 (ko) | 레트로바이러스를 사용한 표적 세포내로의 유전자 도입 방법 | |
US6642043B1 (en) | Double mutants of dihydrofolate reductase and methods of using same | |
Davis et al. | Characterization of the P140K, PVP (138-140) MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy | |
JPH10513441A (ja) | 哺乳類宿主の結合組織を治療するための遺伝子導入 | |
US8912153B2 (en) | HDAC4 nucleic acid administration to treat retinal disease | |
JPH10501989A (ja) | 疾患治療用誘導型一酸化窒素シンターゼ遺伝子 | |
JPH08511507A (ja) | 哺乳動物宿主の結合組織を処置するための遺伝子導入 | |
JP4424857B2 (ja) | リボヌクレオチドレダクターゼのr1及びr2成分に対する抗腫瘍アンチセンス配列 | |
Evans et al. | Gene therapy for arthritis | |
US6268138B1 (en) | Retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs | |
US20080051357A1 (en) | Composition for attenuating neuropathic pain comprising a recombinant ventor expressing gad65 | |
JPH08506722A (ja) | 腫瘍を治療するためのレトロウイルスベクターおよびそれらを含む細胞系統 | |
JPH09505037A (ja) | ガン治療法に関する改良 | |
JP2000507554A (ja) | 治療用アルキル化剤の毒性から保護する遺伝子治療のための変異型アルキルトランスフェラーゼの使用 | |
KR20020013473A (ko) | 아데노바이러스-매개 유전자 치료법 | |
JPH09504518A (ja) | 負の選択マーカーおよびサイトカインをコード化する遺伝子を用いる腫瘍細胞の遺伝子転換による腫瘍の治療 | |
US20040259829A1 (en) | Compositions and methods for sensitizing and inhibiting growth of human tumor cells | |
US6770632B1 (en) | Folypolyglutamyl synthetase gene transfer to enhance antifolate | |
Grez et al. | Gene therapy of chronic granulomatous disease | |
KR20010085261A (ko) | 티로신 키나제 Src를 사용하는, 맥관형성의 조절에유용한 방법 및 조성물 | |
Hayashi et al. | An experimental application of gene therapy for human retinoblastoma. | |
Vrionis et al. | A more potent bystander cytocidal effect elicited by tumor cells expressing the herpes simplex virus—thymidine kinase gene than by fibroblast virus—producer cells in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040305 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070914 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071029 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071018 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071116 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071217 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080625 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080925 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091016 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091112 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091112 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091211 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091222 |